Clinical Trials
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer
Results will be discussed with global health authorities for...
Press Releases
Receptor.AI Announces Collaboration with Sareum to Accelerate Discovery of BBB-Permeable TYK2/JAK1 Inhibitors for Neuroinflammatory Diseases
London, UK — August 14, 2025 — Receptor.AI, an AI- and technology-driven drug discovery company, today announced a strategic collaboration with Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors.
The collaboration will focus on the...
Press Releases
Global healthcare AI experts and former UK Health Minister back AI that detects healthcare-associated infections up to 72 hours earlier
Sanome’s MEMORI becomes the first UK‑built, Certified Class IIb Software-as-a-Medical Device for real-time infection prediction, ahead of NHS rollout and FDA approval.
AI tool that spots hospital infections up to 72 hours early, newly backed by former health minister...
Drug Research
Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research
In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and...
Press Releases
Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins Made in the USA
Sino Biological US, Inc. proudly unveils ProPure™, an industry-leading line of ultra-pure, endotoxin-free recombinant proteins, fully produced in the USA at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas. This new product line is specifically engineered to...
BioPharma
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs...
Clinical Trials
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read